Interview with Willem Dekker , Regional Director, Nycomed Australia
What impact have the PBS reforms had on Nycomed? As most mid size Pharma companies that operate in a setting of mass market prescription medicines, Nycomed is also experiencing the…
Address: 2-4 Lyonpark Road,MACQUARIE PARK NSW 2113,Australia
Tel: 61 (02) 9859 6900
Web: http://www.takedaaustralia.com.au/au/
Building valued partnerships with the medical professionals who prescribe and recommend our products is both Nycomed Australia’s greatest challenge and our greatest reward. These aspirations as well as our commitment to provide medicines that offer real promise to patients, drives us to seek innovative and efficient ways of presenting our products to the Australian market.
Through a commitment to the ethical and professional delivery of quality medical education, Nycomed Australia is continually building valued relationships with the medical community. This is achieved by the creation of focused disease state education programs, and the facilitation of knowledge sharing between thought leaders and primary care practitioners. While Nycomed Australia always strive to keep Somac® (pantoprazole) and Alvesco ® (ciclesonide) at the ‘top of the mind’ of Australian prescribers, activities are often unrelated to their products and instead focus on topics of clearly identified educational needs within the areas of Gastroenterology and Respiratory Medicine.
In addition to building relationships with individual healthcare professionals, Nycomed Australia seeks to develop productive partnerships with the peak bodies that share our therapeutic focus. For example, The Gastroenterology Society of Australia guides us in the field of gastroenterology. In the area of respiratory medicine, Nycomed Australia has developed positive relationships with both the National Asthma Council and the Australian Lung Foundation. Nycomed Australia is also excited by the prospect of pioneering new relationships with peak bodies in emerging areas of therapeutic interest.
As a member of Medicines Australia, Nycomed Australia is devoted to strengthening the pharmaceutical industry’s position as a partner in quality healthcare delivery. This is achieved through the ethical promotion of our products and our support of the Medicines Australia code of conduct. Nycomed and its people are proud of their contribution to the Australian healthcare environment and seek to ensure that their organisation acts as a trusted pharmaceutical partner.
Every day across Australia, our highly trained industry-accredited representatives bring life to our products and services. They are the face of Nycomed Australia.
Nycomed Australia’s professional team is committed to our vision to become the preferred pharmaceutical company by being responsive, reliable and by understanding customer needs.
Gastroenterology and Respiratory Medicine
What impact have the PBS reforms had on Nycomed? As most mid size Pharma companies that operate in a setting of mass market prescription medicines, Nycomed is also experiencing the…
In an exclusive new podcast, DIA Global Forum Australia/New Zealand Regional Editor Richard Day (University of New South Wales, Medicine, St. Vincent’s Hospital) and John Skeritt, Head of Australia’s Therapeutic Goods Administration (TGA),…
Janssen Australia & New Zealand’s Bruce Goodwin argues that greater adoption of patient-centric practices is beneficial to patients, companies and healthcare systems as a whole. Goodwin also gives his five…
Can you start by giving our readers a brief overview of the company’s history here and your most notable achievements? Initially the company was founded as a small distributor of…
Would you begin by outlining the role & importance of George Clinical within the George Institute, highlighting recent milestones & achievements? George Clinical is an important division of the Institute,…
Would you begin by giving an introduction to our international readers of the institute, highlighting recent milestones & achievements and the current focus areas of its research activities? Broadly speaking,…
For those that are not familiar with your name, would you start by introducing yourself? After obtaining my PhD in cardiovascular physiology I moved to Boston to work at MIT…
Rare Voices Australia is a new organisation that has been established after the national rare diseases symposium in 2011. Can you please begin with giving our readers an introduction to…
In some ways the Australian medicines industry is going through the same restructuring and challenges as the industry is going through globally: the country deals with patent cliffs, companies are…
Can you outline the significance of the current PBS to the industry and in particular the impact it has on service providers to the industry such as Hahn? As service…
Speaking to the Australian environment, how would you rate the market in terms of companies like Swisse? After traveling the world, the Australian market has shown to be one of…
In our interviews we have been hearing two opinions on the success of PBS reforms: that it works as it should in providing space for innovative medicine listings, and that…
Dr Bernadette Morris-Smith has also participated in this interview TranScrip Partners is by now a well-established player in the UK but a new player in Asia Pacific. Would you begin…
See our Cookie Privacy Policy Here
